$16,589.76 speaking Payment -- Gilead Sciences to Dr. Karen Harris

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Gilead Sciences made a $16.6K speaking payment to Karen Harris, a Infectious Disease specialist in City, VA. Dr. Karen Harris received $16,589.76 from Gilead Sciences for speaking engagements. The payment was for serving as faculty or a speaker, indicating an educational or informational role. This payment occurred on June 21, 2025, and was processed through the CMS Open Payments system.

Patient Guidance: What This Payment Means for You

Patients should be aware that their healthcare providers may receive compensation for educating others about medical treatments and research. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Payments for speaking engagements can vary widely, but this amount for an infectious disease specialist is moderate to high, depending on the frequency and nature of the speaking events.

Regulatory Context: Sunshine Act Requirements

This payment falls under the Sunshine Act provisions of the Affordable Care Act, requiring disclosure of financial relationships between drug manufacturers and healthcare providers.

Related Topics

This payment is related to the following healthcare transparency topics:

• speaking-fees
• pharmaceutical-payments
• physician-compensation
• infectious-disease
• gilead-sciences
• cms-open-payments

Understanding speaking Payments

Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.

Frequently Asked Questions About This Payment

What was this $16.6K payment for?

This was a speaking payment of $16.6K from Gilead Sciences to Karen Harris, categorized as "Compensation for serving as faculty or as a speaker". The payment was reported under the Sunshine Act (CMS Open Payments).

Does Karen Harris accept pharmaceutical money?

Yes, Karen Harris received this $16.6K payment from Gilead Sciences. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Karen Harris's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this speaking payment?

A speaking payment of $16.6K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Infectious Disease?

To compare this payment against Infectious Disease averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Infectious Disease physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Karen Harris's relationship with Gilead Sciences?

The payment amount is substantial, suggesting a significant speaking commitment. This $16.6K speaking payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Infectious Disease?

The payment type is 'speaking', specifically for faculty or speaker services.

What should patients do after learning about this payment?

Patients should be aware that their healthcare providers may receive compensation for educating others about medical treatments and research.

What else should I know about this speaking payment?

Gilead Sciences, the payer, is a major pharmaceutical company.

Related Reports

• View Dr. Karen Harris's full payment report
• Gilead Sciences full spending report
• Browse all Infectious Disease payments
• Browse all payments in Virginia
• Search for other payments